- Home
- AKTX vs KORE Comparison
AKTX vs KORE Comparison
Compare AKTX & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- KORE
- Stock Information
- Founded
- AKTX N/A
- KORE 2003
- Country
- AKTX United States
- KORE United States
- Employees
- AKTX N/A
- KORE N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- AKTX Health Care
- KORE Consumer Discretionary
- Exchange
- AKTX Nasdaq
- KORE Nasdaq
- Market Cap
- AKTX 35.7M
- KORE 39.3M
- IPO Year
- AKTX N/A
- KORE N/A
- Fundamental
- Price
- AKTX $0.84
- KORE $2.31
- Analyst Decision
- AKTX Strong Buy
- KORE Hold
- Analyst Count
- AKTX 1
- KORE 2
- Target Price
- AKTX $5.00
- KORE $2.75
- AVG Volume (30 Days)
- AKTX 85.8K
- KORE 10.1K
- Earning Date
- AKTX 08-13-2025
- KORE 08-14-2025
- Dividend Yield
- AKTX N/A
- KORE N/A
- EPS Growth
- AKTX N/A
- KORE N/A
- EPS
- AKTX N/A
- KORE N/A
- Revenue
- AKTX N/A
- KORE $285,636,000.00
- Revenue This Year
- AKTX N/A
- KORE $4.46
- Revenue Next Year
- AKTX N/A
- KORE $5.94
- P/E Ratio
- AKTX N/A
- KORE N/A
- Revenue Growth
- AKTX N/A
- KORE 0.24
- 52 Week Low
- AKTX $0.57
- KORE $1.10
- 52 Week High
- AKTX $3.85
- KORE $4.88
- Technical
- Relative Strength Index (RSI)
- AKTX 44.86
- KORE 47.94
- Support Level
- AKTX $0.57
- KORE $2.20
- Resistance Level
- AKTX $1.01
- KORE $2.59
- Average True Range (ATR)
- AKTX 0.07
- KORE 0.14
- MACD
- AKTX -0.00
- KORE 0.00
- Stochastic Oscillator
- AKTX 63.51
- KORE 42.86
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.